News & Updates
Showing Multidisciplinary articles
Showing

Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

HKU programme offers free comprehensive genomic profiling tests to NSCLC patients
The University of Hong Kong (HKU) has launched a precision oncology programme in partnership with public and private stakeholders to provide free comprehensive genomic profiling tests to 1,800 eligible patients with stage IV non-small-cell lung cancer (NSCLC) in Hong Kong. Initial data from the programme revealed less common mutations amenable to treatment with targeted therapies in a sizeable proportion of patients.

Dolutegravir: A better choice for HIV viral suppression in pregnancy?
Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.

Polygenic risk scores predict response to ECT for major depressive disorder
A polygenic liability for major depressive disorder and bipolar disorder contributes to improvements following electroconvulsive therapy (ECT), reports a study. This provides evidence of a genetic factor for clinical response to ECT.




